THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [3.4]-CMP1 ID: TIP-MED-000271

Perindopril Erbumine IP

Active Ingredient / Scientific Identity: Perindopril Erbumine IP • Class: Angiotensin II Receptor Blocker (ARB) (Ester Prodrug)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Perindopril Erbumine IP ([3.4]-CMP1 | ID: TIP-MED-000271) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/3-4-cmp1-perindopril-erbumine-ip/
Generic / Entity NamePerindopril Erbumine IP ([3.4]-CMP1)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassAngiotensin II Receptor Blocker (ARB) (Ester Prodrug)
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Dosing depends on renal function; in severe renal impairment (CrCl <20 mL/min), do not exceed 20 mg once daily. Monito
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Perindopril Erbumine IP (TIP-MED-000271, Reference Code [3.4]-CMP1) is classified under Cardiovascular & Antithrombotic Medicines (Ch 03) as a Angiotensin II Receptor Blocker (ARB) (Ester Prodrug). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-3-27). Long-acting tissue-lipophilic prodrug ACE inhibitor (Coversyl 4/8 mg; active metabolite perindoprilat) used in hypertension, HFrEF, stable CAD (EUROPA), and stroke prevention (PROGRESS).
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-3-27). Long-acting tissue-lipophilic prodrug ACE inhibitor (Coversyl 4/8 mg; active metabolite perindoprilat) used in hypertension, HFrEF, stable CAD (EUROPA), and stroke prevention (PROGRESS).
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-3-27). Long-acting tissue-lipophilic prodrug ACE inhibitor (Coversyl 4/8 mg; active metabolite perindoprilat) used in hypertension, HFrEF, stable CAD (EUROPA), and stroke prevention (PROGRESS).

4. Therapeutic Indications & Evidence-Supported Uses

  • Essential hypertension (monotherapy or in combination with amlodipine/chlorthalidone)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-3-27). Long-acting tissue-lipophilic prodrug ACE inhibitor (Coversyl 4/8 mg; active metabolite perindoprilat) used in hypertension, HFrEF, stable CAD (EUROPA), and stroke prevention (PROGRESS).

Administration & Meal Timing: With or without food. | Once daily at the same time each morning.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [3.4].
Metabolism & Biotransformation:
Renal: Dosing depends on renal function; in severe renal impairment (CrCl <20 mL/min), do not exceed 20 mg once daily. Monitor creatinine and K+. Hepatic: No adjustment in mild hepatic impairment; avoid in severe hepatic impairment or biliary obstruction.
Elimination & Renal Adjustment:
Renal: Dosing depends on renal function; in severe renal impairment (CrCl <20 mL/min), do not exceed 20 mg once daily. Monitor creatinine and K+. Hepatic: No adjustment in mild hepatic impairment; avoid in severe hepatic impairment or biliary obstruction.
Hepatic Impairment Considerations:
Renal: Dosing depends on renal function; in severe renal impairment (CrCl <20 mL/min), do not exceed 20 mg once daily. Monitor creatinine and K+. Hepatic: No adjustment in mild hepatic impairment; avoid in severe hepatic impairment or biliary obstruction.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in pregnancy, biliary obstruction, and co-administration with aliskiren in diabetes. Specific regulatory warning: Sprue-like enteropathy (severe chronic diarrhoea with substantial weight loss occurring months to years after starting olmesartan).

Key Clinical Precautions: Renal: Dosing depends on renal function; in severe renal impairment (CrCl <20 mL/min), do not exceed 20 mg once daily. Monitor creatinine and K+. Hepatic: No adjustment in mild hepatic impairment; avoid in severe hepatic impairment or biliary obstruction.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Dizziness, headache, mild hyperuricaemia, pharyngitis, diarrhoea.
  • Olmesartan-induced sprue-like enteropathy (villous atrophy mimicking celiac disease), severe hyperkalaemia, acute kidney injury, symptomatic hypotension.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Colesevelam (bile acid sequestrant) reduces olmesartan bioavailability—administer olmesartan ≥4 hours before colesevelam
    • NSAIDs, potassium supplements, and spironolactone carry standard ARB interaction risks

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [3.4].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Specifically instruct the patient and family that if unexplained severe chronic watery diarrhoea and weight loss develop—even after taking olmesartan safely for 1–2 years—they must report to the physician immediately so the drug can be switched.
    • Meal & Clock Timing Instruction: With or without food. (Once daily at the same time each morning.)
    • Missed Dose Protocol: Take as soon as remembered on the same day; skip if almost time for the next dose.
    • Geriatric Dispensing Pearl: Potent antihypertensive effect; initiate at 10 mg or 20 mg in elderly CGHS patients to avoid rapid postural blood pressure drops. Always inquire about chronic diarrhoea during repeat refills.

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 10 mg, 20 mg, 40 mg

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

    ← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
    Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/3-4-cmp1-perindopril-erbumine-ip/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.